Cortexyme's atuzaginstat slowed cognitive decline in participants with alzheimer's disease and p. gingivalis infection in phase 2/3 gain trial: additional top-line data presented at ctad 2021

South san francisco, calif.--(business wire)---- $crtx--cortexyme, inc. (nasdaq: crtx) will present additional data from its phase 2/3 gain trial at the 14th clinical trials on alzheimer's disease conference (ctad 2021) as a part of the meeting's late-breaking readout roundtable program today, thursday, november 11, 2021, at 11:35 a.m. eastern time taking place in boston, massachusetts, as well as virtually. the presentation will expand on previously reported top-line results that demonstrated the relati
QNCX Ratings Summary
QNCX Quant Ranking